B Cells and Their Rolexs in Shaping the Immune Response in Squamous Cell Carcinoma of the Head and Neck

ImmunotherapyVol. 13, No. 9 EditorialB cells and their role in shaping the immune response in squamous cell carcinoma of the head and neckPanagiota Economopoulou, Ioannis Kotsantis & Amanda PsyrriPanagiota Economopoulou https://orcid.org/0000-0001-8871-3264Second Department of Internal Medicine, Section of Medical Oncology, National & Kapodistrian University of Athens, Attikon University Hospital, Athens, GreeceSearch for more papers by this author, Ioannis KotsantisSecond Department of Internal Medicine, Section of Medical Oncology, National & Kapodistrian University of Athens, Attikon University Hospital, Athens, GreeceSearch for more papers by this author & Amanda Psyrri*Author for correspondence: Tel.: +30 210 583 1664; E-mail Address: psyrri237@yahoo.comSecond Department of Internal Medicine, Section of Medical Oncology, National & Kapodistrian University of Athens, Attikon University Hospital, Athens, GreeceSearch for more papers by this authorPublished Online:29 Apr 2021https://doi.org/10.2217/imt-2021-0070AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: B cellshead and neck cancerimmune checkpoint inhibitorsimmunotherapyT cellstertiary lymphoid structuresReferences1. Sautes-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19(6), 307–325 (2019).Crossref, Medline, CAS, Google Scholar2. Largeot A, Pagano G, Gonder S, Moussay E, Paggetti J. The B-side of cancer immunity: the underrated tune. Cells 8(5), 449 (2019).Crossref, CAS, Google Scholar3. Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 32(19-20), 1267–1284 (2018).Crossref, Medline, CAS, Google Scholar4. Lechner A, Schlosser HA, Thelen M et al. Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma. Oncoimmunology 8(3), 1535293 (2019).Crossref, Medline, Google Scholar5. Rodriguez-Pinto D. B cells as antigen presenting cells. Cell. Immunol. 238(2), 67–75 (2005).Crossref, Medline, CAS, Google Scholar6. Bruno TC. New predictors for immunotherapy responses sharpen our view of the tumour microenvironment. Nature 577(7791), 474–476 (2020).Crossref, Medline, CAS, Google Scholar7. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Ann. Rev. Immunol. 26, 677–704 (2008).Crossref, Medline, CAS, Google Scholar8. Economopoulou P, Kotsantis I, Psyrri A. Tumor microenvironment and immunotherapy response in head and neck cancer. Cancers (Basel) 12(11), (2020).Crossref, Medline, Google Scholar9. Dieu-Nosjean MC, Giraldo NA, Kaplon H, Germain C, Fridman WH, Sautes-Fridman C. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol. Rev. 271(1), 260–275 (2016).Crossref, Medline, CAS, Google Scholar10. Lechner A, Schlosser H, Rothschild SI et al. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma. Oncotarget 8(27), 44418–44433 (2017).Crossref, Medline, Google Scholar11. Sharonov GV, Serebrovskaya EO, Yuzhakova DV, Britanova OV, Chudakov DM. B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nat. Rev. Immunol. 20(5), 294–307 (2020).Crossref, Medline, CAS, Google Scholar12. Zhou X, Su YX, Lao XM, Liang YJ, Liao GQ. CD19(+)IL-10(+) regulatory B cells affect survival of tongue squamous cell carcinoma patients and induce resting CD4(+) T cells to CD4(+)Foxp3(+) regulatory T cells. Oral Oncol. 53, 27–35 (2016).Crossref, Medline, CAS, Google Scholar13. Norouzian M, Mehdipour F, Balouchi Anaraki S, Ashraf MJ, Khademi B, Ghaderi A. Atypical memory and regulatory B cell subsets in tumor draining lymph nodes of head and neck squamous cell carcinoma correlate with good prognostic factors. Head Neck Pathol. 14(3), 645–656 (2020).Crossref, Medline, Google Scholar14. Wieland A, Patel MR, Cardenas Ma et al. Defining HPV-specific B cell responses in patients with head and neck cancer. Nature (2020). https://doi.org/10.1038/s41586-020-2931-3Crossref, Medline, Google Scholar15. Helmink BA, Reddy SM, Gao J et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577(7791), 549–555 (2020).Crossref, Medline, CAS, Google Scholar16. Cabrita R, Lauss M, Sanna A et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577(7791), 561–565 (2020).Crossref, Medline, CAS, Google Scholar17. Petitprez F, De Reynies A, Keung EZ et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577(7791), 556–560 (2020).Crossref, Medline, CAS, Google Scholar18. Iglesia MD, Parker JS, Hoadley KA, Serody JS, Perou CM, Vincent BG. Genomic analysis of immune cell infiltrates across 11 tumor types. J. Natl Cancer Inst. 108(11), djw144 (2016).Crossref, Google Scholar19. Iglesia MD, Vincent BG, Parker JS et al. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin. Cancer Res. 20(14), 3818–3829 (2014).Crossref, Medline, CAS, Google Scholar20. Varn Fs, Wang Y, Cheng C. A B cell-derived gene expression signature associates with an immunologically active tumor microenvironment and response to immune checkpoint blockade therapy. Oncoimmunology 8(1), e1513440 (2019).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetails Vol. 13, No. 9 Follow us on social media for the latest updates Metrics Downloaded 97 times History Received 26 March 2020 Accepted 18 April 2021 Published online 29 April 2021 Published in print June 2021 Information© 2021 Future Medicine LtdKeywordsB cellshead and neck cancerimmune checkpoint inhibitorsimmunotherapyT cellstertiary lymphoid structuresFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download